Ardelyx, Inc. (ARDX) Stock Price & Analysis
Ardelyx, Inc. (ARDX) fell 1.95% to USD 5.03 as of July 25, 2026 at 04:49 UTC, according to Nexqual real-time market data.
ARDX last closed at USD 5.13; the session ranged USD 5.02–5.17 on volume of 1,576,326 shares. Market capitalization is $1.24B, with a 52-week range of USD 4.08–8.4 (NGM). Source: Nexqual, July 25, 2026 at 04:49 UTC.
Key Statistics (as of July 25, 2026 at 04:49 UTC)
| Price | USD 5.03 |
|---|---|
| Change | ▼ 1.95% (down) |
| Previous Close | USD 5.13 |
| Open | USD 5.15 |
| Day Range | USD 5.02 – 5.17 |
| 52-Week Range | USD 4.08 – 8.4 |
| Volume | 1,576,326 shares |
| Market Cap | $1.24B |
| Exchange | NGM |
Technical Analysis (ARDX)
Nexqual's technical model rates ARDX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.33 (neutral) |
| vs SMA50 | Below (USD 5.66) |
| MACD | -0.18 (negative) |
Analyst Ratings (ARDX)
Wall Street analysts rate ARDX "Strong Buy" based on 10 analysts, with a mean price target of USD 16.3 (range USD 13–19), per Nexqual as of July 25, 2026 at 04:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 16.3 |
| High Target | USD 19 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (ARDX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $122.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.14 ▼ miss |
| 2025-12-31 | USD 0 vs est 0.01 ▼ miss |
| 2025-09-30 | USD 0 vs est -0.07 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.14 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Financials & Fundamentals (ARDX)
| Total Revenue | $427.68M |
|---|---|
| Revenue Growth (YoY) | +27.50% |
| Gross Margin | +74.56% |
| Operating Margin | -34.71% |
| Profit Margin | -13.58% |
| ROE | -39.46% |
| Debt / Equity | 157.53 |
| Current Ratio | 3.49 |
| Total Cash | $238.07M |
| Total Debt | $234.13M |
| Free Cash Flow | $86,375 |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Financial Health Score (ARDX)
Nexqual rates Ardelyx, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:49 UTC.
| Growth | Strong — Revenue +22% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -35% |
| Balance Sheet | Weak — $238M cash vs $234M debt, net cash position |
| Cash Flow | Mixed — FCF $86K, slim 0.0% margin |
| Efficiency | Critical — ROE -39%, ROA -5.1% |
Ownership (ARDX)
| Insider Ownership | +3.26% |
|---|---|
| Institutional Ownership | +70.80% |
| Shares Outstanding | 247.03M |
| Float | 219.80M |
| Short % of Float | +10.50% |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Leadership (ARDX)
Ardelyx, Inc. is led by Michael G. Raab (age 60), President, CEO & Director, per Nexqual as of July 25, 2026 at 04:49 UTC.
| President, CEO & Director | Michael G. Raab (age 60) |
|---|---|
| Chief Financial Officer | Sue Hohenleitner (age 54) |
| Vice President of Corporate Communications & Investor Relations | Caitlin Lowie |
Major Backers & Investors (ARDX)
Notable institutional backers of Ardelyx, Inc. include Millennium Management, Janus Henderson Group PLC, Nomura Asset Management International Inc, according to Nexqual as of July 25, 2026 at 04:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 7.22% |
| Janus Henderson Group PLC | 3.39% |
| Nomura Asset Management International Inc | 3.31% |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.7% |
| Two Sigma Investments, LP | 1.73% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.81% |
| BlackRock | 11.67% |
| State Street | 8.5% |
| Geode Capital | 2.43% |
| Nuveen | 2.12% |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
From Ardelyx, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
- The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
- Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | USD 1.22 | ▼ 3.17% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.52 | ▼ 10.59% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| TGTX | TG Therapeutics, Inc. | USD 56.04 | ▲ 6.38% |
| KALA | KALA BIO, Inc. | USD 0.63 | ▼ 13.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:49 UTC. This page is informational and not investment advice.